ChengDu ShengNuo Biotec Co.,Ltd. (SHSE: 688117)
Health Care · Pharmaceuticals · CN
CN¥25.79
-4.59% today · -17.7% 1Y
ChengDu ShengNuo Biotec Co.,Ltd. (SHSE: 688117) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $845.32M and employs 1,605 people.
Over the last twelve months the share price has lost 17.7%, trading between 20.91 and 33.21.
Tweenvest scores ChengDu ShengNuo Biotec Co.,Ltd. across four factors: quality 62/100, value 55/100, growth 63/100, dividend 37/100. Its strongest factor is growth.
688117 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $845.32M
- Revenue (TTM)
- $134.13M
- P/E
- 27.88
- EPS
- 0.93
- Dividend yield
- 0.97%
- Beta (5Y)
- 0.55
- 52-week high
- CN¥33.21
- 52-week low
- CN¥20.91
- Avg volume (3M)
- —
- Shares outstanding
- 220.34M
- Employees
- 1,605
- Next earnings
- —
About ChengDu ShengNuo Biotec Co.,Ltd.
ChengDu ShengNuo Biotec Co.,Ltd. focuses on the entire lifecycle of peptide pharmaceuticals, from initial research and development to manufacturing, and their subsequent domestic and international distribution. The company's product portfolio encompasses active polypeptide ingredients (APIs), solid dosage tablets, and a diverse range of injectable formats, including freeze-dried powders, small-volume solutions, pre-filled syringes, and specialized card-type injections. This enterprise was established in 2001 and conducts its operations from Chengdu, China.
- ISIN
- CNE1000051M8
- Founded
- 2001
- Listed since
- Jun 3, 2021
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.